Monoclonal antibodies lock down SARS-CoV-2 spike
- PMID: 37805348
- DOI: 10.1016/j.it.2023.09.006
Monoclonal antibodies lock down SARS-CoV-2 spike
Abstract
SARS-CoV-2 rapidly accumulated mutations in its immunodominant receptor-binding domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective. Liu et al. unveil potent human mAbs that neutralize all tested SARS-CoV-2 variants by locking the Spike protein RBD in a downward conformation, thus inhibiting receptor engagement.
Keywords: Omicron; SARS-CoV-2; broadly neutralizing antibody; cryo-EM; monoclonal antibodies.
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests No interests are declared.
Comment on
-
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.Immunity. 2023 Oct 10;56(10):2442-2455.e8. doi: 10.1016/j.immuni.2023.09.003. Epub 2023 Sep 29. Immunity. 2023. PMID: 37776849 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous